Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Haas on the Role of PSMA in Prostate Cancer

November 14th 2020

Naomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.

Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate Cancer

November 12th 2020

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Enzalutamide Approved in China for Nonmetastatic Castration-Resistant Prostate Cancer

November 11th 2020

November 10, 2020 - The China National Medical Products Administration has approved enzalutamide for the treatment of adult patients with nonmetastatic castration-resistant prostate cancer who are at a higher risk of metastasis.

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

November 10th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Dr. Beltran on the Significance of Genomic Sequencing in Prostate Cancer

November 9th 2020

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Olaparib in Prostate Cancer

November 9th 2020

The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic with olaparib, which is indicated for select patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

Active Surveillance Found Feasible Among African Americans With Low-Risk Prostate Cancer

November 9th 2020

African American men with low-risk prostate cancer who received active surveillance had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment compared with non-Hispanic white men.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

November 5th 2020

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Olaparib Approved in Europe for BRCA+ Metastatic Castration-Resistant Prostate Cancer

November 5th 2020

The European Union has approved olaparib for use in patients with metastatic castration-resistant prostate cancer who harbor BRCA1/2 mutations.

Hussain Discusses Progress of PARP Inhibition in Metastatic Castration-Resistant Prostate Cancer

November 5th 2020

PARP inhibitors have emerged as a promising therapeutic target in prostate cancer at the 38th Annual CFS® virtual conference.

Dr. Baskin on Racial Disparities and Early Screening in Prostate Cancer

November 4th 2020

Monica L. Baskin, PhD, discusses the roles of race and early screening in prostate cancer.

Dr. Beltran on the Need to Identify Non–AR Targets in Prostate Cancer

November 3rd 2020

Himisha Beltran, MD, discusses the need to identify non–androgen receptor targets in prostate cancer.

Dr. Mahal on the Prevalence of Prostate Cancer in African American Men

November 2nd 2020

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men.

FDA Lifts Hold on Phase 1 Trial of CAR T-Cell Therapy P-PSMA-101 in mCRPC

November 2nd 2020

The FDA has lifted the clinical hold placed on the phase 1 PSMA-101-001 study of the CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC

October 29th 2020

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Treatment Based on Advanced Molecular Imaging Can Improve DFS in Prostate Cancer

October 28th 2020

The use of advanced molecular imaging with the PET radiotracer fluciclovine (18F) to inform treatment decisions can lead to improved disease-free survival rates in patients with recurrent prostate cancer.

Dr. Theurillat on Castration and AR Inhibition in Prostate Cancer

October 27th 2020

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.

Dr. Lin on the Role of Genomic Markers in Prostate Cancer

October 27th 2020

Daniel W. Lin, MD, discusses the role of genomic markers in prostate cancer.

Dr. Abdulkadir on the Rationale to Target MYC in Prostate Cancer

October 27th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the rationale to target MYC in prostate cancer.